All In Biotech

Drug Trial Radar · NCT00659100

A Trial to Assess Consumer Self-Selection and Use of Gabapentin for Occasional Sleeplessness in an Over-the-Counter Environment

A 3-Month, Open-Label, Pharmacy-Based, Actual-Use Trial in a Simulated Over-The-Counter (OTC) Environment to Assess Self-Selection and Consumer Use Patterns of Gabapentin 250 mg for Occasional Sleeplessness

Last checked: Nov 19, 2026Latest source record: Feb 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,254

Actual

Start

Aug 2006

Primary completion

Not stated

Study completion Jan 2007

Sponsor

Sponsor type
Industry
First posted
Apr 16, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess consumers' behaviors related to gabapentin self- selection and use, relative to warnings and directions for use, as described in the proposed over-the-counter (OTC) product label.

Conditions

  • Transient Insomnia

Interventions

  • GabapentinDrug

    Gabapentin 50 mg oral capsule 30 minutes before bedtime

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects who selected or purchased gabapentin for use (patients had symptoms consistent with indication and no contraindications)Time frame: Throughout Day 90
  2. Subject compliance with directions for use (number of capsules per dose and the number of doses per day)Time frame: Throughout Day 90

Locations

35 sites in 1 country. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Anaheim, California

  • Pfizer Investigational Site

    Bonita, California

  • Pfizer Investigational Site

    Fallbrook, California

  • Pfizer Investigational Site

    Hacienda Heights, California

  • Pfizer Investigational Site

    La Mesa, California

  • Pfizer Investigational Site

    Oceanside, California

  • Pfizer Investigational Site

    Orange, California

  • Pfizer Investigational Site

    San Dimas, California

  • Pfizer Investigational Site

    Pembroke Pines, Florida

  • Pfizer Investigational Site

    Weston, Florida

  • Pfizer Investigational Site

    Baltimore, Maryland

  • Pfizer Investigational Site

    Elk River, Minnesota

  • Pfizer Investigational Site

    Northfield, Minnesota

  • Pfizer Investigational Site

    Red Wing, Minnesota

  • Pfizer Investigational Site

    Saint Louis Park, Minnesota

  • Pfizer Investigational Site

    Holly Springs, Mississippi

  • Pfizer Investigational Site

    Belton, Missouri

  • Pfizer Investigational Site

    Independence, Missouri

  • Pfizer Investigational Site

    Albuquerque, New Mexico

  • Pfizer Investigational Site

    Albuquerque, New Mexico

  • Pfizer Investigational Site

    Taos, New Mexico

  • Pfizer Investigational Site

    Cary, North Carolina

  • Pfizer Investigational Site

    Chapel Hill, North Carolina

  • Pfizer Investigational Site

    Raleigh, North Carolina

  • Pfizer Investigational Site

    Raleigh, North Carolina

  • Pfizer Investigational Site

    Raleigh, North Carolina

  • Pfizer Investigational Site

    Houston, Texas

  • Pfizer Investigational Site

    Pearland, Texas

  • Pfizer Investigational Site

    Bountiful, Utah

  • Pfizer Investigational Site

    Ogden, Utah

  • Pfizer Investigational Site

    Salt Lake City, Utah

  • Pfizer Investigational Site

    Syracuse, Utah

  • Pfizer Investigational Site

    West Valley City, Utah

  • Pfizer Investigational Site

    Falls Church, Virginia

  • Pfizer Investigational Site

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.